A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Hospital Universitario 12 De Octubre · Hospital Universitario Virgen Macarena · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
641
total citations
- FWCI
- 38.16
- Percentile
- 100%
- References
- 22
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Medicine
- Pembrolizumab
- Oncology
- Placebo
- Protocol (science)
- Internal medicine
- Chemotherapy
- Randomized controlled trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- APAstellas Pharma US
- AAstraZeneca
- BBayer
- MMerck
- NNovartis
- RRoche
- SSanofi
- SPSpectrum Pharmaceuticals
- CCelgene
- AAbbVie
- FHF. Hoffmann-La Roche
- TPTakeda Pharmaceuticals U.S.A.
- BIBoehringer Ingelheim
- LLLes Laboratories Pierre Fabre
- APAstellas Pharma
- SServier
- PPharmaMar
- OPOno Pharmaceutical
- IIpsen
- GGenentech
- MSMerck Sharp and Dohme
- CPChugai Pharmaceutical